NCT02500914View on ClinicalTrials.gov

SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

August 23, 2018

Study Completion Date

August 23, 2018

Conditions
Small Cell Lung Cancer
Interventions
DRUG

SC-002

SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks

Trial Locations (4)

10065

New York

37203

Nashville

48109

Ann Arbor

63110

St Louis

Sponsors

Lead Sponsor

Stemcentrx
All Listed Sponsors
lead

Stemcentrx

INDUSTRY